Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Baxter International Inc BAX

Healthcare Medical Devices
Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. Its Healthcare Systems and Technologies segment includes... see more

Recent & Breaking News (NYSE:BAX)

Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis

PR Newswire June 12, 2015

Baxter's Commitment to Innovative Programs and Advancing Its Sustainability Priorities Featured in Sixteenth Report

Business Wire June 10, 2015

CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA

PR Newswire June 10, 2015

Baxter Announces Effectiveness of Baxalta Form 10 Registration Statement

Business Wire June 9, 2015

Baxter's Board of Directors Approves Separation of Baxalta and Declares Special Dividend of Baxalta Stock

Business Wire June 5, 2015

Baxter Ventures, Mayo Clinic and Velocity Pharmaceutical Development Announce the Formation of Vitesse Biologics, LLC, a Company Structured to Accelerate Therapeutic Innovation

Business Wire June 1, 2015

Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation

PR Newswire June 1, 2015

Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015

PR Newswire May 30, 2015

Baxter Presents Data Demonstrating Remote Technology May Help Reduce Barriers to Home Therapy

Business Wire May 29, 2015

Baxter and Baxalta Executives to Present at the Goldman Sachs 36th Annual Global Healthcare Conference

Business Wire May 28, 2015

Baxter BioScience Files for European Approval of Investigational 20% Subcutaneous Immune Globulin Treatment for Primary Immunodeficiency

Business Wire May 21, 2015

Baxter and Baxalta Highlight Business Strategies at Investor Conferences

Business Wire May 18, 2015

Baxter Receives U.S. FDA Approval for 0.9% Sodium Chloride Injection, USP from Sabinanigo, Spain, Facility for the U.S. Market

Business Wire May 15, 2015

Economists Anthony Culyer and Alan Maynard Named Co-Recipients of the 2015 William B. Graham Prize for Health Services Research

Business Wire May 13, 2015

Baxter BioScience to Expand Global Oncology Footprint with Acquisition of Oncaspar® Portfolio for Leukemia

Business Wire May 12, 2015

Baxter to Host May 2015 Investor Conferences

Business Wire May 11, 2015

Baxter Declares Quarterly Dividend

Business Wire May 5, 2015

PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients

PR Newswire May 4, 2015

Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an Investigational Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer

Business Wire May 4, 2015

Baxter to Host May 2015 Investor Conferences

Business Wire May 1, 2015